CMS to Bridge coverage for obesity drugs as BALANCE teeters

April 22, 2026

CMS to Bridge coverage for obesity drugs as BALANCE teeters

When the U.S. CMS didn’t get takers for its voluntary Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model to cover obesity drugs under Medicare Part D, the agency punted. It announced late April 21 that it will indefinitely delay the BALANCE model in Medicare but extend its temporary Medicare GLP-1 Bridge demonstration model through the end of 2027. (The Medicaid BALANCE model will still kick in this year in states that choose to participate in it.)

Source: bioworld

Publication

The World Dispatch

Source: World News API

Keywords: endocrine/metabolic, part d, eli lilly and co., novo nordisk a/s, u.s., analysis and data insight, medicare, bioworld, obesity, cms, wegovy, coverage, payment model, peptide, zepbound, policy, foundayo, glp-1, regulatory, ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS